---
title: 'Regulatory Daily Summary: What Happened on November 8, 2026'
headline: FDA grants priority review to uniQure’s Huntington’s gene-therapy application
description: A Senate discussion draft would also change how the FDA reviews software-based
  and integrated medical devices.
url: https://thebench.bio/news/regulatory/2026-11-08
topic: regulatory
date: '2026-11-08'
covers:
- '2026-11-08'
date_published: '2026-11-08T12:00:40Z'
date_modified: '2026-11-09T00:00:51Z'
tags:
- Regulatory
- Software
sources: 2
publisher: TheBench.Bio
---

# Regulatory Daily Summary: What Happened on November 8, 2026

**FDA grants priority review to uniQure’s Huntington’s gene-therapy application**

A Senate discussion draft would also change how the FDA reviews software-based and integrated medical devices.

## Today in brief

The FDA accepted uniQure’s application for AMT-130, its Huntington’s disease gene therapy, and granted it priority review. [1] Senator Bill Cassidy announced a discussion draft proposing new FDA review options for software-based and integrated medical devices. [2]

## Also worth knowing

- AMT-130 uses an AAV5 vector to deliver an artificial microRNA designed to silence the Huntingtin gene. Treatment requires neurosurgery, and neuroinflammation occurred in some patients. [1]
- The draft would allow voluntary preliminary review of device components, establish risk-based review for software devices and create an accredited third-party review program. Its authors say the proposals’ practical value will depend on implementation. [2]

## The day in numbers

- **180 days**: Time the draft would give the FDA after enactment to issue guidance on component review and low- to moderate-risk software devices. [2]
- **30 days**: Time the draft would give the FDA to accept a third-party determination or decide that further review is appropriate. [2]

## Sources

1. [Weekly reads: Huntington’s treatment hope, AI & the idea of a science paper, misuse of 3-parent IVF (MRT), death of young stem cell biologist](<https://ipscell.com/2026/11/weekly-reads-ai-the-idea-of-a-science-paper-misuse-of-3-parent-ivf-mrt-huntingtons-hope-death-of-young-stem-cell-biologist/?utm_source=rss&utm_medium=rss&utm_campaign=weekly-reads-ai-the-idea-of-a-science-paper-misuse-of-3-parent-ivf-mrt-huntingtons-hope-death-of-young-stem-cell-biologist>), The Niche, 2026-11-08
2. [The PATIENT AI Act: A New Prescription for FDA Software Review, or More of the Same?](<https://www.thefdalawblog.com/2026/11/the-patient-ai-act-a-new-prescription-for-fda-software-review-or-more-of-the-same/?utm_source=rss&utm_medium=rss&utm_campaign=the-patient-ai-act-a-new-prescription-for-fda-software-review-or-more-of-the-same>), FDA Law Blog, 2026-11-08

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://ipscell.com/2026/11/weekly-reads-ai-the-idea-of-a-science-paper-misuse-of-3-parent-ivf-mrt-huntingtons-hope-death-of-young-stem-cell-biologist/?utm_source=rss&utm_medium=rss&utm_campaign=weekly-reads-ai-the-idea-of-a-science-paper-misuse-of-3-parent-ivf-mrt-huntingtons-hope-death-of-young-stem-cell-biologist>
[2]: <https://www.thefdalawblog.com/2026/11/the-patient-ai-act-a-new-prescription-for-fda-software-review-or-more-of-the-same/?utm_source=rss&utm_medium=rss&utm_campaign=the-patient-ai-act-a-new-prescription-for-fda-software-review-or-more-of-the-same>